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ABSTRACT:
The goal of the current grant is to investigate the potential antitumor activity of histone deacetylase inhibitor MS-275 along with the activation of TGFb signaling pathway with the restoration of TGFb receptor II. As presented in our initial proposal, prostate cancer cell line LNCaP has reduced expression in TGFbRII, which is due to the promoter histone deacetylation. Subsequent treatment with chromatin remodeling agent MS-275 was able to restore the expression of TGFbRII. We hypothesized that the restoration of TGFb signaling may contribute to the antitumor activity of MS-275. In the past a year and half, we have focused our effort to identify the re-expression of Final Report:
Introduction:
The goal of the current grant is to investigate the potential antitumor activity of histone deacetylase inhibitor MS-275 along with the activation of TGFb signaling pathway with the restoration of TGFb receptor II. As presented in our initial proposal, prostate cancer cell line LNCaP has reduced expression in TGFbRII, which is due to the promoter histone deacetylation. Subsequent treatment with chromatin remodeling agent MS-275 was able to restore the expression of TGFbRII. We hypothesized that the restoration of TGFb signaling may contribute to the antitumor activity of MS-275. In the first one and half year of study, we had focused our effort to identify the re-expression of TGFbRII in vivo, and investigate the antitumor activity of MS-275 in several relevant prostate cancer model. Since the last progress report, we have focused our effort to demonstrate a) the epigenetic mechanism of TGFbRII expression by HDAC inhibitors, b) the effect of HDAC inhibitors on androgen receptor signaling.
Body:
Specific Aim 1): To determine whether loss of TGFβRII expression in a human prostate carcinoma cell line is due to transcriptional epigenetic repression.
To demonstrate the loss of expression of TFGBRII in LNCaP cells, we performed chromatin immunoprecipitation assay (CHIP). As shown in Figure 1C , the promoter region of TGFBRII and its primary ligand TGFb1 were un-acetylated in control (drug free) condition. Addition of MS-275 at 1 and 2 uM increased the promoter acetylation, which corresponds to the upregulation of the gene expression (as demonstrated in figure 1A 1B). The current CHIP assay ( figure 1C ) complements with the previous RT-PCR results (figure 1a 1b), establish the epigenetic silencing nature of these two genes in prostate cancer LNCaP cells.
Specific Aim 2): To determine whether re-expression of TGFβRII by HDACI is associated with the restoration of TGFβ signaling and contributes to HDACI antitumor activity.
We also examined the TGFbRII expression levels in other prostate cancer cell lines -PC3, LAPC4, and DU145. All these cell lines exhibited robust expression level of TGFBRII and its ligands. HDAC inhibitors could not further upregulate the expression. In addition, the Smad pathway components that downstream of TGFBRII signaling in all these cell lines were not altered by the HDAC inhibition. Therefore, we concluded that the upregulation of TGFBRII signaling by HDAC inhibitors were limited to the LNCaP cells. In vitro, cell proliferation assays confirmed statistically significant inhibition over single agents when HDAC inhibitors were combined with exogenous TGFb1 (figure 2). However, due to the fact that HDAC inhibitors also target many growth pathways that are independent of TGFBRII signaling, there were significant levels of inhibition on the growth of cancer cells both in vitro and in vivo regardless of the TGFBRII status (table 1, figure 3, 4 and 6).
The conclusion, therefore, is that HDAC inhibitors may upregulate TGFBRII that partially mediates the antitumor activity of HDAC inhibitors.
Specific Aim 3): To evaluate the antitumor effect of HDACIs in combination with anti-androgen treatment (androgen ablation).
Our initial hypothesis is that HDAC inhibitors may synergies with androgen ablation therapy. However during our in vitro experiments and clinical trials of HDAC inhibitors in prostate cancer patients, we observed that HDAC inhibitor's antitumor activity does not complement with the reduction of androgen ablation. In vitro, HDAC inhibitors may upregulate PSA expression, which is a target gene of androgen signaling pathway under total growth factor and androgen starvation condition (table 2), but not in full serum condition (figure 5). The possible modulation of PSA by HDAC inhibitors has not been fully investigated. Under our experimental conditions, we did not observed PSA induction in hormone sensitive cell lines at the gene expression level, but we observed increased protein levels in LAPC4 treated cells. These results suggest a possible PSA modulation by MS-275 at the posttranscriptional level, or perhaps by increasing its secretion. Further studies will be necessary to elucidate this observation. The induction of PSA protein level in association with inhibition of cell proliferation following in vitro MS-275 treatment suggest that changes in PSA levels should not be considered a primary endpoint in clinical trials involving HDAC inhibitors. However, PSA induction may represent a readable biological effect of HDAC inhibition and a potential biomarker for drug exposure. Although a clinical role of HDAC inhibitors is already a reality, their general clinical utility will likely depend greatly on the future development of molecular or cellular predictors of their antitumor activity. Molecular targeted combination therapies of post-transcription modifiers such HDAC inhibitors with standard therapies (chemotherapy and radiation therapy) and novel biologics including angiogenesis inhibitor represent an exciting challenge. Understanding the nature of the molecular basis of the selectivity of HDACs and designing specific HDACs inhibitors will be critical to further exploit the potential of this novel class of agents in the treatment of solid tumors including prostate cancer.
Chromatin Immunoprecipitation PCR (CHIP) Figure 1C .
LNCaP cells were treated with 1 or 2 uM of MS-275 for 24 hours, cells were subject to CHIP assay using Acetyl-H4 antibody (Upstate) based on the protocol included in the CHIP assay kit (Upstate), and DNA fragments containing acetyl-H4 were amplified using PCR primers specific for TGFb1 and TGFbRII promoters. Total DNA without acetyl-H4 immunoprecipitation was used as positive input control.
